Published Guidance, NICE advice and quality standards

Skip to filtersSkip to results

Skip to results

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 551 to 600 of 761

TitleReference numberPublishedLast updated
Nivolumab in combination with ipilimumab for treating advanced melanomaTA400
Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicatedTA387
Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemiaTA393
Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemiaTA394
Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancerTA395
Trametinib in combination with dabrafenib for treating unresectable or metastatic melanomaTA396
Adalimumab for treating moderate to severe hidradenitis suppurativaTA392
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetesTA390
Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fractionTA388
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancerTA389
Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosisTA386
Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)TA23
Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemiaTA385
Nivolumab for treating advanced (unresectable or metastatic) melanomaTA384
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritisTA383
Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicatedTA377
Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapyTA378
Nintedanib for treating idiopathic pulmonary fibrosisTA379
Panobinostat for treating multiple myeloma after at least 2 previous treatmentsTA380
Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal)TA382
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failedTA375
Guidance on the use of imatinib for chronic myeloid leukaemiaTA70
Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tearsTA369
Bortezomib for previously untreated mantle cell lymphomaTA370
Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritisTA373
Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapyTA374
Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis CTA365
Vortioxetine for treating major depressive episodesTA367
Ledipasvir–sofosbuvir for treating chronic hepatitis CTA363
Tolvaptan for treating autosomal dominant polycystic kidney diseaseTA358
Idelalisib for treating chronic lymphocytic leukaemiaTA359
Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal)TA362
Vedolizumab for treating moderately to severely active Crohn's disease after prior therapyTA352
Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal)TA353
Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolismTA354
Naloxegol for treating opioid‑induced constipationTA345
Aflibercept for treating diabetic macular oedemaTA346
Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancerTA347
Everolimus for preventing organ rejection in liver transplantationTA348
Secukinumab for treating moderate to severe plaque psoriasisTA350
Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal)TA351
Omalizumab for previously treated chronic spontaneous urticariaTA339
Vedolizumab for treating moderately to severely active ulcerative colitisTA342
Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolismTA341
Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemiaTA343
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndromeTA335
Empagliflozin in combination therapy for treating type 2 diabetesTA336
Rifaximin for preventing episodes of overt hepatic encephalopathyTA337
Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapyTA329
Sofosbuvir for treating chronic hepatitis CTA330

Results per page

  1. 10
  2. 25
  3. 50
  4. All